

## Special Issue

# Diagnosis, Monitoring, and Treatment of Chronic Myeloid Leukemia

### Message from the Guest Editor

It is well known that chronic myeloid leukemia (CML) has been the prototype for targeted therapy in oncology. From the publication of the IRIS study in 2003 to recent data with Asciminib, the CML-treating community has strived to improve not only the life expectancy but also the quality of life of our patients. Given your significant contribution to the field we are pleased to invite you to contribute to this multidisciplinary Special Issue of *Current Oncology* focusing on CML. This Special Issue aims at focusing on the history of CML, state-of-the-art management including real-world evidence, and future areas of research. We would like to call upon colleagues from the worlds of nursing and pharmacy, as well as physicians and scientists. Current topics under consideration include new diagnostic criteria and treatment guidelines based on new data and real-world evidence. Also to be incorporated will be review articles on the psychosocial aspect of the disease, drug-drug interactions, and the management of toxicities or our therapies. We look forward to receiving your contributions.

### Guest Editor

Dr. Lynn Savoie

Departments of Medicine and Oncology, University of Calgary, Calgary, AB, Canada

### Deadline for manuscript submissions

31 August 2025



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/si/223990](https://mdpi.com/si/223990)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[curroncol](https://mdpi.com/journal/currentoncology)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/journal/  
currentcol](https://mdpi.com/journal/currentcol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)